Quantcast
Last updated on April 18, 2014 at 17:24 EDT

A Finnish Company Enters International Markets With World Class Genetics Technology

June 12, 2013

HELSINKI, June 12, 2013 /PRNewswire/ –

Blueprint Genetics has launched a new genetic testing technology for professional use
in hospitals. The gene sequencing technology is based on Stanford University research and
can effectively analyse rare hereditary human diseases. The company started its operations
in 2012 in Helsinki.

The tests of Blueprint Genetics enable efficient diagnosis of difficult hereditary
diseases. Today there are almost 4000 recognized diseases with a genetic background. The
results of genetic tests will help physicians in reaching their diagnoses, predicting the
course of the disease, choosing treatments, and efficient screening of relatives. The
first tests of Blueprint Genetics focus on hereditary cardiovascular diseases.

The company aims to bring genetic diagnostics into the daily routines of healthcare
organizations by lowering the barrier to start using genetic testing. This will be enabled
by offering tests that are more comprehensive, more cost-effective and faster than
existing tests. The geneticists and clinicians at Blueprint Genetics will interpret the
test results and give statements directly to the treating physicians within three weeks
from sample reception.

Blueprint Genetics targets international diagnostics markets and will begin its
operations in the EU area. The international recommendations for the use of genetic
diagnostics are increasing rapidly and current research advocates comprehensive testing
for hereditary diseases. According to Blueprint Genetics, there have never been so
comprehensive, or easy-to-use tests available for a price level that is feasible for
clinical use.

The company has a strong background in medical genetics research. “Finland is a great
place to start an international genetics growth company. We have a huge amount of
knowledge and resources in Finland and the genetics research is globally recognized,” says
Tommi Lehtonen, CEO of Blueprint Genetics.

Blueprint Genetics provides advanced professional genetic testing for rare diseases.
The company started its operations in 2012 and provides diagnostics for cardiovascular,
neurological and eye disorders. Currently the company employs 11 employees and is based in
Helsinki, Finland.

        More information:

        Tommi Lehtonen
        CEO
        Blueprint Genetics Oy
        +358-44-7700-411
        tommi.lehtonen@blueprintgenetics.com

http://www.blueprintgenetics.com

SOURCE Blueprint Genetics


Source: PR Newswire